Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

@article{Geller2011DevelopmentOA,
  title={Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.},
  author={David E. Geller and Jeffry Weers and Silvia Heuerding},
  journal={Journal of aerosol medicine and pulmonary drug delivery},
  year={2011},
  volume={24 4},
  pages={175-82}
}
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the high treatment burden in this patient population. PulmoSphere™ technology is an emulsion-based spray-drying process that enables the production of light porous particle, dry… CONTINUE READING
66 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Aerosol performance of tobramycin inhalation powder

  • A Haynes, J Nakamura, C Heng, S Heuerding, G Thompson, R Malcolmson
  • Respiratory Drug Delivery
  • 2010

Basic immunological properties of spray-dried lipid microparticles developed for nasal and systemic administration of vaccines

  • L Wang, S Bot, +4 authors A Bot
  • STP Pharma Sci. 2002;12:53–61. Received on…
  • 2010

Beyond the throat: preferred methods of assessing regional distribution in the lung

  • AR Clark
  • Respiratory Drug Delivery
  • 2010

Effects of device design on patient compliance: comparing the same drug in different devices

  • H Chrystyn
  • Respiratory Drug Delivery Europe
  • 2009

Similar Papers

Loading similar papers…